Skip to main content

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.

Publication ,  Journal Article
George, DJ; Ramaswamy, K; Huang, A; Russell, D; Mardekian, J; Schultz, NM; Janjan, N; Freedland, SJ
Published in: Prostate Cancer Prostatic Dis
September 2022

BACKGROUND: Black men are more likely to be diagnosed with aggressive prostate cancer (PC) and die from PC than white men. However, black men with metastatic castration-resistant PC (mCRPC) had longer overall survival (OS) than white men when treated with certain agents in clinical trials. We analyzed claims data from the Veterans Health Administration (VHA) database to evaluate OS in black and white men treated with enzalutamide or abiraterone (novel hormonal therapy [NHT]) for chemotherapy-naïve mCRPC. METHODS: Patients with mCRPC aged ≥18 years were identified in the VHA database by diagnosis codes, evidence of surgical/medical castration, and a prescription claim for enzalutamide or abiraterone after castration from April 2014-March 2017. Cox models assessed associations between race and OS. Unadjusted and multivariable analyses were performed on the entire population and subsets based on the type of therapy received (if any) after NHT. RESULTS: In total, 2910 patients were identified (787 black, mean 71.7 years; 2123 white, mean 74.0 years). Median follow-up was 19.0 and 18.7 months in blacks and whites, respectively. Black men had better survival versus white men: hazard ratios (95% CIs) were 0.89 (0.790-0.996; P = 0.044) and 0.67 (0.592-0.758; P < 0.0001) in the unadjusted and multivariable models, respectively. Statistically significantly longer OS was seen in black versus white men regardless of subsequent treatment, including no subsequent treatment. CONCLUSIONS: In the VHA, black men with chemotherapy-naïve mCRPC initiating NHT may have better outcomes than similarly treated white men.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

September 2022

Volume

25

Issue

3

Start / End Page

524 / 530

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Prostatic Neoplasms, Castration-Resistant
  • Phenylthiohydantoin
  • Nitriles
  • Male
  • Humans
  • Benzamides
  • Antineoplastic Combined Chemotherapy Protocols
  • Androstenes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
George, D. J., Ramaswamy, K., Huang, A., Russell, D., Mardekian, J., Schultz, N. M., … Freedland, S. J. (2022). Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis, 25(3), 524–530. https://doi.org/10.1038/s41391-021-00463-9
George, Daniel J., Krishnan Ramaswamy, Ahong Huang, David Russell, Jack Mardekian, Neil M. Schultz, Nora Janjan, and Stephen J. Freedland. “Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.Prostate Cancer Prostatic Dis 25, no. 3 (September 2022): 524–30. https://doi.org/10.1038/s41391-021-00463-9.
George DJ, Ramaswamy K, Huang A, Russell D, Mardekian J, Schultz NM, et al. Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):524–30.
George, Daniel J., et al. “Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.Prostate Cancer Prostatic Dis, vol. 25, no. 3, Sept. 2022, pp. 524–30. Pubmed, doi:10.1038/s41391-021-00463-9.
George DJ, Ramaswamy K, Huang A, Russell D, Mardekian J, Schultz NM, Janjan N, Freedland SJ. Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):524–530.

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

September 2022

Volume

25

Issue

3

Start / End Page

524 / 530

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Prostatic Neoplasms, Castration-Resistant
  • Phenylthiohydantoin
  • Nitriles
  • Male
  • Humans
  • Benzamides
  • Antineoplastic Combined Chemotherapy Protocols
  • Androstenes